Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no add ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

My recent coverage of UroGen Pharma (NASDAQ: URGN ) was the prospective risk-taker's manifesto on a very shaky FDA decision. Now that this thesis has worked out, the "predictions" laid out in that article appear to be nearlyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the p ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Holdings (NYSE: CODI) between May 1, 2024, and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Compass securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Core Insights - Adobe Inc. reported second-quarter revenue of $5.87 billion, exceeding analyst estimates of $5.79 billion, and adjusted earnings of $5.06 per share, surpassing the expected $4.96 per share [1][2] - The company raised its full-year 2025 revenue guidance to a range of $23.5 to $23.6 billion, up from the previous guidance of $23.3 billion to $23.55 billion, and adjusted earnings guidance to $20.50 to $20.70 per share, increased from $20.20 to $20.50 per share [3] Financial Performance - For the third quarter, Adobe expects revenue between $5.88 billion and $5.93 billion, compared to estimates of $5.87 billion, and anticipates adjusted earnings of $5.15 to $5.20 per share, against estimates of $5.10 per share [2] - Following the earnings announcement, Adobe shares fell by 5.8% to $389.64 [3] Analyst Ratings and Price Targets - Wells Fargo analyst Michael Turrin maintained an Overweight rating and raised the price target from $430 to $470 [6] - Oppenheimer analyst Brian Schwartz maintained an Outperform rating but lowered the price target from $530 to $500 [6] - Evercore ISI Group analyst Kirk Materne reiterated an Outperform rating with a maintained price target of $475, while BMO Capital analyst Keith Bachman also reiterated an Outperform rating with a price target of $450 [6]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Core Insights - The fintech sector is rapidly evolving, with Block, Inc. and Upstart Holdings emerging as key players due to their innovative business models and growth strategies [1][2] Group 1: Block, Inc. Overview - Block is expanding its fintech platform through Square and Cash App, providing comprehensive solutions across payments, commerce, and banking [3] - Innovations such as the Square Point of Sale app and "Cash App Afterpay" highlight Block's focus on user-centric design and revenue diversification [3] - The company is enhancing its omnichannel seller tools and has FDIC-approved lending capabilities, targeting younger users and families [4] Group 2: Challenges Facing Block - Block is experiencing macroeconomic challenges, including tariffs and reduced discretionary spending, which are impacting Cash App Card activity [5] - Despite a forecasted improvement in gross profit, near-term performance is affected by competition from PayPal, Shopify, and new fintech entrants [5][6] Group 3: Upstart Holdings Overview - Upstart is differentiating itself in the lending space by utilizing AI-driven credit modeling instead of traditional FICO scores, automating 92% of loans [7] - The company has expanded its loan portfolio to include auto loans, HELOCs, and small-dollar loans, achieving double-digit growth in Q1 2025 [8] - Upstart's AI engine is evolving, with Model 19 improving borrower behavior predictions and conversion rates increasing from 14% to 19% [9] Group 4: Financial Performance of Upstart - Upstart reported a 67% year-over-year revenue increase and achieved profitability with a non-GAAP EPS of $0.30 in Q1 2025 [9] - The company is increasingly relying on super-prime borrowers, which enhances funding consistency and reduces risk [9] Group 5: Comparative Estimates and Valuation - The Zacks Consensus Estimate for Block indicates a 3.55% sales growth and a 25.22% decline in EPS for 2025, with downward revisions noted [12] - In contrast, Upstart's 2025 sales are expected to grow by 58.8%, with EPS estimates trending upward [12][14] - Year-to-date, Upstart shares have decreased by 11.4%, while Block shares have declined by 24.9% [16] Group 6: Conclusion - Block's established ecosystem faces challenges from soft consumer demand and competition, while Upstart demonstrates stronger operational leverage and growth potential [19] - Upstart is positioned as the fintech stock with greater upside potential for long-term investors seeking innovation-led growth [19][20]

Crown Holdings (CCK) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...

Investors might want to bet on Verve Therapeutics (VERV) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changi ...

Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individua ...